Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Tau biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

The assay demonstrated robust quantification of BD-Tau in CSF, plasma, and serum with measured concentrations ranging from 3 to 20 pg/mL across 15 paired plasma and serum samples. Serum levels were ∼10% lower than plasma concentrations but showing strong correlation (Spearman r = 0.74; p = 0.002). Median intra- and inter-assay CV% were below 10% across six independent runs with measurements done in duplicate, on calibrator, spiked buffer and plasma samples. The LLOQ was determined to be 0.78 pg/mL based on precision profile. Lot-to-lot variability was below 10%. Significant correlation with the BD-Tau SIMOA assay was observed (Spearman r = 0.89; p < 0.0001), with superior discriminatory power for AD versus controls in a first exploratory assessment using the plasma samples (Xplorer assay AUC: 0.69 vs SIMOA assay AUC: 0.59). The BD-Tau Xplorer kit provides accurate and reproducible quantification of BD-Tau on an automated platform. Further validation in larger and more differentiated cohorts is warranted to evaluate its context of use and value as a potential marker for prognosis and monitoring disease progression, not only in AD but across neurological diseases.

What this study adds

Evidence grade: Moderate

The authors state that further validation in larger and more differentiated cohorts is needed before its value as a marker for prognosis and monitoring can be established, and no treatment or cure is reported. Reported effect size: AUC: 0.69; AUC: 0.59.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Vanbrabant, J., Van Loo, M., Blancke, N., Antwi‐Berko, D., van der Flier, W. M., Verberk, I. M., et al. (2025). Analytical Qualification of the BD‐Tau Xplorer kit on LUMIPULSE® G1200. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_105432

Vancouver

Vanbrabant J, Van Loo M, Blancke N, Antwi‐Berko D, van der Flier WM, Verberk IM, et al. Analytical Qualification of the BD‐Tau Xplorer kit on LUMIPULSE® G1200. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_105432. PMID: 41518608.

BibTeX

@article{vanbrabant2025-41518608,
  author  = {Vanbrabant, Jeroen and Van Loo, Maxime and Blancke, Nathan and Antwi‐Berko, Daniel and van der Flier, Wiesje M. and Verberk, Inge M.W. and Teunissen, Charlotte Elisabeth and Stoops, Erik},
  title   = {{Analytical Qualification of the BD‐Tau Xplorer kit on LUMIPULSE® G1200}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_105432},
  pmid    = {41518608},
  url     = {https://doi.org/10.1002/alz70856_105432}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This study describes the analytical qualification of the BD-Tau Xplorer kit on an automated platform, showing accurate and reproducible measurement of BD-Tau in cerebrospinal fluid, plasma and serum, with an exploratory assessment showing better discrimination of Alzheimer's disease versus controls than a comparison assay. The authors state that further validation in larger and more differentiated cohorts is needed before its value as a marker for prognosis and monitoring can be established, and no treatment or cure is reported.

Study details

How this study scored 38/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 3 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 38 of 100.38 of 100 points earned62 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Erik Stoops: h-index 34 (OpenAlex, whole career)
Institution's track record 1 / 3 Vrije Universiteit Amsterdam: institution h-index 1,014 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41518608)
Free to read 2 / 2 Free to read
Total 38 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Tau biomarkers from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →